---
document_datetime: 2023-09-21 18:35:04
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/ariclaim-epar-procedural-steps-taken-authorisation_en.pdf
document_name: ariclaim-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.8784371
conversion_datetime: 2025-12-22 09:28:49.544848
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company Boehringer Ingelheim International GmbH submitted on 7 February 2003 an application for  Marketing Authorisation to the European Medicines Agency (EMEA) for Ariclaim, through the centralised  procedure.  After  agreement  by  the  CHMP  on  17-19  September  2002,  this  medicinal product has been referred to Part B of the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993.

•

The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Dr. Calvo Rojas Co-Rapporteur: Dr. Salmonson Scientific Advice: The applicant received Scientific Advice from the CHMP on 19 November 1998. The Scientific Advice pertained to clinical aspects of the dossier. Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 24 February 2003. · The Rapporteur's first assessment report was circulated to all CHMP Members on 6 May 2003. The Co-Rapporteur's first assessment report was circulated to all CHMP Members on 6 May 2003. · During  the  meeting  on  24-26  June  2003,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  26 June 2003. · The  company  submitted  the  responses  to  the  consolidated  list  of  questions  on  14  November 2003. · The Rapporteur circulated the response assessment report on the company's responses to the list of questions to all CHMP Members on 23 December 2003. · During the CHMP meeting on 20-22 January 2004, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant. · The applicant submitted the responses to the CHMP list of outstanding issues on 9 February 2004. Medicinal product no longer authorised

During the meeting on  23-25 March 2004, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Ariclaim on 24 March 2004. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 24 March 2004.

- On 25 May 2004, a case of suicide attempt in a 43 year-old female patient in an open label phase III study was reported. The issue was brought to the attention of the CHMP during its meeting on 1-3 June 2004.
- The  Commission,  at  the  request  of  the  EMEA,  put  the  Standing  Committee  phase  on  hold pending the outcome of the CHMP discussion regarding the new safety information.

<div style=\"page-break-after: always\"></div>

- During the meeting on 22-23 June 204 the CHMP, in the light of the overall data submitted and the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Ariclaim on 23 June 2004.
- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 11 August 2004.

## Medicinal product no longer authorised